IMGN Immunogen

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded in March 1981 and is headquartered in Waltham, MA.
Company profile
Ticker
IMGN
Exchange
Website
CEO
Mark Enyedy
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
IMMUNOGEN INC
SEC CIK
Corporate docs
IRS number
42726691
IMGN stock data
()
News
ImmunoGen US Patent & Trademark Office Abstract For Co.'s 'SELECTIVE SULFONATION OF BENZODIAZEPINE DERIVATIVES'
8 Apr 21
72 Biggest Movers From Yesterday
17 Feb 21
64 Biggest Movers From Friday
16 Feb 21
12 Health Care Stocks Moving In Friday's Intraday Session
12 Feb 21
Stocks That Hit 52-Week Highs On Friday
12 Feb 21
Press releases
ImmunoGen Presents Preclinical Data on IMGC936 at the AACR Virtual Annual Meeting
10 Apr 21
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 Apr 21
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1 Mar 21
ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference
24 Feb 21
ImmunoGen Reports Recent Progress and 2020 Financial Results
12 Feb 21
Calendar
1 Mar 21
11 Apr 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from Immunogen earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 293.86M | 293.86M | 293.86M | 293.86M | 293.86M | 293.86M |
Cash burn (monthly) | (positive/no burn) | (positive/no burn) | (positive/no burn) | 1.87M | (positive/no burn) | 6.55M |
Cash used (since last report) | n/a | n/a | n/a | 6.29M | n/a | 22.1M |
Cash remaining | n/a | n/a | n/a | 287.56M | n/a | 271.75M |
Runway (months of cash) | n/a | n/a | n/a | 154.2 | n/a | 41.5 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Mar 21 | Mitchell Dean J | Deferred Share Unit Common Stock | Grant | Aquire A | No | No | 0 | 1,666 | 0 | 93,774 |
31 Mar 21 | Goldberg Mark Alan | Deferred Share Unit Common Stock | Grant | Aquire A | No | No | 0 | 1,666 | 0 | 109,876 |
5 Feb 21 | Renee Lentini | Common Stock Common Stock | Grant | Aquire A | No | No | 7.69 | 80,800 | 621.35K | 80,800 |
5 Feb 21 | Berkenblit Anna | Common Stock Common Stock | Grant | Aquire A | No | No | 7.69 | 282,019 | 2.17M | 282,019 |
5 Feb 21 | Stacy Ann Coen | Common Stock Common Stock | Grant | Aquire A | No | No | 7.69 | 185,016 | 1.42M | 185,016 |
Institutional ownership Q4 2020
Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.
86.6% owned by funds/institutions
13F holders |
Current |
---|---|
Total holders | 205 |
Opened positions | 41 |
Closed positions | 19 |
Increased positions | 56 |
Reduced positions | 72 |
13F shares |
Current |
---|---|
Total value | 1.12B |
Total shares | 172.9M |
Total puts | 465.8K |
Total calls | 451.9K |
Total put/call ratio | 1.0 |
Largest owners |
Shares | Value |
---|---|---|
Wellington Management | 22.08M | $142.44M |
Ra Capital Management | 18.42M | $118.79M |
BLK Blackrock | 15.16M | $97.76M |
Vanguard | 14.16M | $91.31M |
FMR | 12.54M | $80.9M |
Redmile | 10.53M | $67.91M |
STT State Street | 8.8M | $56.79M |
Clearbridge Advisors | 6.89M | $44.46M |
MS Morgan Stanley | 4.65M | $29.97M |
Renaissance Technologies | 4.24M | $27.32M |
Financial report summary
?Competition
Pfizer • Astrazeneca • Seagen • Glaxosmithkline • Stemline Therapeutics • Daiichi Sankyo • Sutro Biopharma • Mersana Therapeutics • Kintara Therapeutics • Xenetic BiosciencesContent analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Academy, accessibility, AgreementSM, Alexion, alter, Altschuller, ample, antileukemia, authoritative, Biden, BIO, Bioverativ, camptothecin, capillary, career, Coen, compendia, CRc, Darden, Enterprise, evergreen, Factoring, folate, graduate, Hangzhou, home, Hong, Huadong, Huntington, interface, intolerance, investor, Kong, leak, linked, LogicBio, Macau, MBA, mortality, NaN, outset, perspective, poster, PR, predetermined, predominantly, prejudice, proportionate, racism, reenacted, relinquishing, Republic, reward, source, Stacy, sublet, Susan, syndrome, synergistic, Taiwan, teen, twenty, Virginia, Viridian, virtual, Wall, weaken, weather, workplace, xenograft, Zhongmei
Removed:
affiliate, aggregating, alternatively, anniversary, assured, batch, Bermuda, book, build, cancelled, choice, collectability, commanding, commensurate, compare, comparing, conservative, Cowen, creation, crosslinking, deliverable, discounted, discover, DMx, documented, doxorubicin, element, eligibility, enabling, enhancement, equally, establishment, expensing, feature, finalized, flexibility, forego, foundation, GCC, inauguration, indatuximab, input, invalidated, lab, lieu, liposomal, long, maximum, medium, mid, mitigated, optioned, paclitaxel, pegylated, pembrolizumab, PFS, placement, plant, predicated, preferred, preparing, privately, profit, prompt, ran, reclassed, recognizable, referenced, Reinvestment, reliably, replace, replaced, retrospectively, revaluation, revalue, revert, segregate, shipped, short, SPA, statistical, strong, subset, TCJA, tenant, thereunder, topotecan, triple, unaudited, undelivered, underway, unilateral, unrecognizable, waive, weekly, wide
Financial reports
10-K
2020 FY
Annual report
1 Mar 21
10-Q
2020 Q3
Quarterly report
6 Nov 20
10-Q
2020 Q2
Quarterly report
5 Aug 20
10-Q
2020 Q1
Quarterly report
5 May 20
10-K
2019 FY
Annual report
11 Mar 20
10-Q
2019 Q3
Quarterly report
5 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
28 Feb 19
10-Q
2018 Q3
Quarterly report
2 Nov 18
Current reports
8-K
Top-Line Data from Pivotal SORAYA Trial for Mirvetuximab Soravtansine in Ovarian Cancer Expected in Q3 2021; BLA to be Submitted by Year-End
12 Feb 21
8-K
Results of Operations and Financial Condition
11 Jan 21
8-K
Entry into a Material Definitive Agreement
18 Dec 20
8-K
Other Events
18 Dec 20
8-K
Other Events
11 Dec 20
8-K
ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting
7 Dec 20
8-K
ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results
6 Nov 20
8-K
Departure of Directors or Certain Officers
26 Oct 20
8-K
ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China
19 Oct 20
8-K
Other Events
13 Oct 20
Registration and prospectus
S-8
Registration of securities for employees
1 Mar 21
S-8
Registration of securities for employees
21 Dec 20
424B5
Prospectus supplement for primary offering
18 Dec 20
S-3ASR
Automatic shelf registration
18 Dec 20
424B5
Prospectus supplement for primary offering
25 Sep 20
424B5
Prospectus supplement for primary offering
23 Jan 20
424B5
Prospectus supplement for primary offering
22 Jan 20
S-8
Registration of securities for employees
20 Dec 19
S-8
Registration of securities for employees
20 Dec 19
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Dec 19
Proxies
DEFA14A
Additional proxy soliciting materials
3 Jun 20
DEFA14A
Additional proxy soliciting materials
28 Apr 20
DEF 14A
Definitive proxy
28 Apr 20
PRE 14A
Preliminary proxy
17 Apr 20
DEFA14A
Additional proxy soliciting materials
30 Apr 19
DEF 14A
Definitive proxy
30 Apr 19
DEF 14A
Definitive proxy
30 Apr 18
DEFA14A
Additional proxy soliciting materials
29 Apr 18
DEF 14A
Definitive proxy
27 Apr 17
DEFA14A
Additional proxy soliciting materials
27 Apr 17
Other
CT ORDER
Confidential treatment order
30 Apr 20
CT ORDER
Confidential treatment order
6 Dec 19
CT ORDER
Confidential treatment order
6 Dec 19
CT ORDER
Confidential treatment order
19 Mar 19
CT ORDER
Confidential treatment order
18 Mar 19
CT ORDER
Confidential treatment order
25 Sep 18
CT ORDER
Confidential treatment order
11 Jun 18
CT ORDER
Confidential treatment order
23 May 18
CT ORDER
Confidential treatment order
21 Feb 18
CT ORDER
Confidential treatment order
12 Dec 17
Ownership
4
ImmunoGen / Mark Alan Goldberg ownership change
2 Apr 21
4
ImmunoGen / DEAN J MITCHELL ownership change
2 Apr 21
SC 13G/A
ImmunoGen / Redmile ownership change
16 Feb 21
SC 13G
ImmunoGen / RA CAPITAL MANAGEMENT ownership change
15 Feb 21
SC 13G/A
ImmunoGen / RENAISSANCE TECHNOLOGIES ownership change
10 Feb 21
SC 13G/A
ImmunoGen / VANGUARD ownership change
10 Feb 21
4
ImmunoGen / Mark J Enyedy ownership change
9 Feb 21
4
ImmunoGen / Susan ALTSCHULLER ownership change
9 Feb 21
4
ImmunoGen / Theresa Wingrove ownership change
9 Feb 21
4
ImmunoGen / Stacy Ann Coen ownership change
9 Feb 21
Patents
APP
Utility
Selective Sulfonation of Benzodiazepine Derivatives
8 Apr 21
The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group.
GRANT
Utility
Methods of preparing substituted 12a,13-dihydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indoles
6 Apr 21
Inventors: Baudouin Gérard, Richard A. Silva, Michael Louis Miller, Manami Shizuka
APP
Utility
Conjugates of Cysteine Engineered Antibodies
25 Mar 21
The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA.
APP
Utility
Camptothecin Derivatives
18 Mar 21
Disclosed herein are novel cytotoxic compounds, and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents.
GRANT
Utility
Benzodiazepine derivatives
16 Mar 21
The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic.
Transcripts
2020 Q4
Earnings call transcript
12 Feb 21
2020 Q3
Earnings call transcript
6 Nov 20
2020 Q2
Earnings call transcript
31 Jul 20
2020 Q1
Earnings call transcript
1 May 20
2019 Q4
Earnings call transcript
14 Feb 20
2019 Q3
Earnings call transcript
1 Nov 19
2019 Q2
Earnings call transcript
2 Aug 19
2019 Q1
Earnings call transcript
3 May 19
2018 Q4
Earnings call transcript
8 Feb 19
2018 Q3
Earnings call transcript
2 Nov 18
Reddit threads
Expected Biotech News 13 April 2021 to 17 June 2021 and PDUFA List for 26 April 2021 to 15 June 2021
10 Apr 21
ACRR Info For $THTX, $AGEN, $ADXS, $IMGN, $CLVS, $CRDF, $EPIX, $MEIP, $PHIO and $GLYC
10 Apr 21
CIDM penny stock, I think it can go to the moon
30 Mar 21
Stay Gold? STAY GREEN! Watchlist 2/12/2021
12 Feb 21
Daily Discussion Thread - February 12th, 2021
12 Feb 21
"The worst stocks are doing the best"
11 Feb 21
Daily Discussion Thread - February 11th, 2021
11 Feb 21
Daily Discussion Thread - February 10th, 2021
10 Feb 21
Daily Discussion Thread - February 9th, 2021
9 Feb 21
Daily Discussion Thread - November 6th, 2020
6 Nov 20